VANCOUVER, British Columbia, May 19, 2009 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) is pleased to announce that it has entered into a Collaborative Research Agreement ("CRA") with The University of British Columbia ("UBC"). The primary purpose of the CRA is to develop and test an ELISA assay to detect concentration levels of the protein "p97" in blood. This is a critical step in the process of BTI obtaining Regulatory Approval for p97 as a Biomarker for Alzheimer's and a Physician's Aid To Diagnose Alzheimer's. The test, if successful, will provide a quick and accurate method to help Physicians diagnose and monitor Alzheimer's. Additionally, this test may also be used to monitor the effectiveness of therapeutics used to treat the disease. Standard Operating Procedures will be developed around the assay, which will be supplied for distribution to clinical laboratories as part of the license terms with BTI.
